Chemistry:BPI-16350
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | BPI16350 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H32F2N8 |
| Molar mass | 518.617 g·mol−1 |
BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer.[1][2] It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.[3]
References
- ↑ Gao, Shuiping; Liu, Ru-Jiao; Chen, Yang; Wang, Yi-qian; Chen, Hong; Zhang, Hui-juan; Ma, Tian-yi; Wang, Jia-bing et al. (28 March 2022). A novel potent CDK4/6 inhibitor BPI-16350 in preclinical cancer models. doi:10.21203/rs.3.rs-1333630/v1.
- ↑ Ray-Coquard, Isabelle; Monk, Bradley J.; Lorusso, Domenica; Mahdi, Haider; Upadhyay, Vivek; Graul, Regina; Husain, Amreen; Mirza, Mansoor Raza et al. (31 October 2023). "The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma" (in en). International Journal of Gynecologic Cancer 33 (12): 1943–1949. doi:10.1136/ijgc-2023-004739. ISSN 1048-891X. PMID 37907262. https://ijgc.bmj.com/content/early/2023/10/31/ijgc-2023-004739.
- ↑ Zhang, Jian; Liu, Rujiao; Gao, Shuiping; Chen, Wenyan; Han, Xinghua; Ma, Yanjie; Ding, Lieming; Wang, Jiabing et al. (1 June 2023). "BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.". Journal of Clinical Oncology 41 (16_suppl): e13051. doi:10.1200/JCO.2023.41.16_suppl.e13051.
 |  |
